Trial Profile

A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EBC-129 (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Appendiceal cancer; Colorectal cancer; Gastric cancer; Lung cancer; Oesophageal cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

05 Feb 2026 Planned number of patients changed from 95 to 98.
03 Jun 2025 According to Experimental Drug Development Centre media release, data from the trial were presented at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
03 Jun 2025 Results (n=21) presented in the Experimental Drug Development Centre Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com